Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

PLoS ONE

Volumn 3, Issue 10, 2008, Pages

  Croyle, Maria A ^a   Patel, Ami ^b,c   Tran, Kaylie ^b   Gray, Michael ^b   Zhang, Yi ^d   Strong, James E ^b,c   Feldmann, Heinz ^b,c   Kobinger, Gary P ^b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; EBOLA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; MACROGOL DERIVATIVE; VIROSOME;

ARTICLE; B LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; EBOLA VIRUS; EBOLA ZAIRE VIRUS; EXPRESSION VECTOR; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INNATE IMMUNITY; LUNG LAVAGE; MOUSE; NONHUMAN; SURVIVAL RATE; T LYMPHOCYTE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRUS CAPSID; ACTIVE IMMUNIZATION; ADENOVIRUS; ANIMAL; ANIMAL DISEASE; ANTIBODY PRODUCTION; C57BL MOUSE; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG EFFECT; EVALUATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; METHODOLOGY; MUCOSAL IMMUNITY; PATHOLOGY; PHYSIOLOGY; SURVIVAL; VIRUS HEMORRHAGIC FEVER;

ADENOVIRIDAE; ANIMALIA; EBOLA VIRUS; HUMAN ADENOVIRUS; MIRIDAE; MUS;

ADENOVIRIDAE; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODY FORMATION; BRONCHOALVEOLAR LAVAGE FLUID; DRUG DELIVERY SYSTEMS; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNITY, MUCOSAL; IMMUNOTHERAPY, ACTIVE; MICE; MICE, INBRED C57BL; POLYETHYLENE GLYCOLS; SURVIVAL ANALYSIS; VIROSOMES;

EID: 56149115867     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0003548     Document Type: Article

References (60)

1. Boyer JL, Kobinger G, Wilson JM, Crystal RG (2005) Adenovirus-based genetic vaccines for biodefense. Hum Gene Ther 16: 157-168.
2. Gallo P, Dharmapurim S, Cipriani B, Monaci P (2005) Adenovirus as vehicle for anticancer genetic immunotherapy. Gene Ther 12: S84-S91.
3. Liniger M, Zuniga A, Naim HY (2007) Use of viral vectors for the development of vaccines. Expert Rev Vaccines 6: 255-266.
4. Papp Z, Babiuk LA, Baca-Estrada ME (1999) The effect of pre-existing adenovirus-specific immunity on immune responses induced by recombinant adenovirus expressing glycoprotein D of bovine herpesvirus type 1. Vaccine 17: 933-943.
5. Xiang ZQ, Gao GP, Reyes-Sandoval A, Li Y, Wilson JM, et al. (2003) Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 2003 77: 10780-10789.
6. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, et al. (2003) Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77: 799-803.
7. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense, et al. (2004) Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 172: 6290-6297.
8. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, et al. (2006) Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology 346: 394-401.
9. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield, et al. (2003) Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 77: 6305-6313.
10. Kresge KJ (2005) Clinical trials yield promising results from two adenovirus-based vaccines. IAVI Rep 9: 24.
11. Nwanegbo E, Vardas E, Gao W, Whittle H, Sun, et al. (2004) Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 11: 351-357.
12. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654-4663.
13. Hartman ZC, Appledorn DM, Amalfitano A (2008) Adenovirus vector induced innate immune responses: Impact upon efficacy and toxicity in gene therapy and vaccine applications. Virus Res 132: 1-14.
14. Osten P, Grinevich V, Cetin A (2007) Viral vectors: a wide range of choices and high levels of service. Handb Exp Pharmacol 1788: 177-202.
15. Xiang Z, Li Y, Gao G, Wilson JM, Ertl HC (2003) Mucosally delivered E1-deleted adenoviral vaccine carriers induce transgene product-specific antibody responses in neonatal mice. J Immunol 171: 4287-4293.
16. Vogels R, Zuijdgeest D, van Rijnsoever R, Hartkoorn E, Damen I, et al. (2003) Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity. J Virol 77: 8263-8271.
17. Kostense S, Koudstaal W, Sprangers M, Weverling GJ, Penders, et al. (2004) Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector. AIDS 18: 1213-1216.
18. Holterman L, Vogels R, van der Vlugt R, Sieuwerts M, Grimbergen, et al. (2004) Novel replication-incompetent vector derived from adenovirus type 11 (Ad11) for vaccination and gene therapy: low seroprevalence and non-cross-reactivity with Ad5. J Virol 78: 13207-13215.
19. Hashimoto M, Boyer JL, Hackett NR, Wilson JM, Crystal RG (2005) Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity. Infect Immun 73: 6885-6891.
20. Lemckert AA, Sumida SM, Holterman L, Vogels R, Truitt DM, et al. (2005) Immunogenicity of heterologous prime-boost regimens involving recombinant adenovirus serotype 11 (Ad11) and Ad35 vaccine vectors in the presence of anti-ad5 immunity. J Virol 79: 9694-9701.
21. Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, et al. (2006) Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17: 500-506.
22. Youil R, Toner TJ, Su Q, Chen M, Tang A, et al. (2002) Hexon gene switch strategy for the generation of chimeric recombinant adenovirus. Hum Gene Ther 13: 311-320.
23. Roberts DM, Nanda A, Havenga MJ, Abbink P, Lynch DM, et al. (2006) Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441: 239-243.
24. Beer SJ, Matthews CB, Stein CS, Ross BD, Hilfinger JM, et al. (1998) Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo. Gene Ther 5: 740-746.
25. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth, et al. (1999) PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 10: 1349-1358.
26. Croyle MA, Chirmule N, Zhang Y, Wilson JM (2001) "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol 75: 4792-4801.
27. Croyle MA, Chirmule N, Zhang Y, Wilson JM (2002) PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum Gene Ther 13: 1887-1900.
28. Sailaja G, HogenEsch H, North A, Hays J, Mittal SK (2002) Encapsulation of recombinant adenovirus into alginate microspheres circumvents vector-specific immune response. Gene Ther 9: 1722-1729.
29. Steel JC, Cavanagh HM, Burton MA, Kalle WH (2004) Microsphere-liposome complexes protect adenoviral vectors from neutralising antibody without losses in transfection efficiency, in-vitro. J Pharm Pharmacol 56: 1371-1378.
30. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta, et al. (2005) PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 12: 579-587.
31. Eto Y, Gao JQ, Sekiguchi F, Kurachi S, Katayama K, et al. (2005) PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J Gene Med 7: 604-612.
32. Santosuosso M, McCormick S, Xing Z (2005) Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18: 283-291.
33. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-609.
34. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, et al. (2006) A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13: 1267-1277.
35. Sullivan NJ, Geisbert TW, Geisbert JB, Shedlock DJ, Xu L, et al. (2006) Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. PLoS Med 3: e177. Epub 2006 May 2016..
36. Bukreyev A, Yang L, Zaki SR, Shieh WJ, Rollin PE, et al. (2006) A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol 80: 2267-2279.
37. Patel A, Zhang Y, Croyle M, Tran K, Gray M, et al. (2007) Mucosal delivery of adenovirus-based vaccine protects against Ebola virus infection in mice. J Infect Dis 196: S413-S420.
38. Croyle MA, Yu QC, Wilson JM (2000) Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum Gene Ther 11: 1713-1722.
39. Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, et al. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25: 2984-2989.
40. Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J (1998) A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis 178: 651-661.
41. Hoenen T, Groseth A, Kolesnikova L, Theriault S, Ebihara H, et al. (2006) Infection of naive target cells with virus-like particles: implications for the function of ebola virus VP24. J Virol 80: 7260-7264.
42. Rao M, Matyas GR, Grieder F, Anderson K, Jahrling PB, et al. (1999) Cytotoxic T lymphocytes to Ebola Zaire virus are induced in mice by immunization with liposomes containing lipid A. Vaccine 17: 2991-2998.
43. Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, et al. (2001) Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol 125: 233-242.
44. Cheng X, Ming X, Croyle MA (2003) PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm Res 20: 1444-1451.
45. Johnson E, Jaax N, White J, Jahrling P (1995) Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus. Int J Exp Pathol 76: 227-236.
46. Jaax NK, Davis KJ, Geisbert TJ, Vogel P, Jaax GP, et al. (1996) Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure. Arch Pathol Lab Med 120: 140-155.
47. Mohamadzadeh M, Chen L, Schmaljohn AL (2007) How Ebola and Marburg viruses battle the immune system. Nat Rev Immunol 7: 556-567.
48. Kiyono H, Fukuyama S (2004) NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 4: 699-710.
49. Lefrançois L, Puddington L (2006) Intestinal and pulmonary mucosal T cells: local heroes fight to maintain the status quo. Annu Rev Immunol 24: 681-704.
50. Neutra MR, Kozlowski PA (2006) Mucosal Vaccines: The Promise and the Challenge. Nat Rev Immunol 6: 148-158.
51. Appaiahgari MB, Saini M, Rauthan M, Vrati J, Vrati S (2006) Immunization with recombinant adenovirus synthesizing the secretory form of Japanese encephalitis virus envelope protein protects adenovirus-exposed mice against lethal encephalitis. Microbes Infect 8: 92-104.
52. Zhou D, Cun A, Li Y, Xiang Z, Ertl HC (2006) A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 14: 662-672.
53. Duncan SJ, Gordon FC, Gregory DW, McPhie JL, Postlethwaite, et al. (1978) Infection of mouse liver by human adenovirus type 5. J Gen Virol 40: 45-61.
54. Wortmann A, Vöhringer S, Engler T, Corjon S, Schirmbeck R, et al. (2008) Fully Detargeted Polyethylene Glycol-coated Adenovirus Vectors Are Potent Genetic Vaccines and Escape from Pre-existing Anti-adenovirus Antibodies. Mol Ther. 2007 Sep 11. Mol Ther 16: 154-162.
55. Prüss-Ustün A, Rapiti E, Hutin Y (2005) Estimation of the global burden of disease attributable to contaminated sharps injuries among health-care workers. Am J Ind Med 48: 482-490.
56. Iwasaki T, Itamura S, Nishimura H, Sato Y, Tashiro M, et al. (2004) Productive infection in the murine central nervous system with avian influenza virus A (H5N1) after intranasal inoculation. Acta Neuropathol 108: 485-492.
57. Gerdts V, Littel-van den Hurk SD, Griebel PJ, Babiuk LA (2007) Use of animal models in the development of human vaccines. Future Microbiol 2: 667-675.
58. Reed DS, Mohamadzadeh M (2007) Status and challenges of filovirus vaccines. Vaccine 25: 1923-1934.
59. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, et al. (2007) Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine. Vaccine 25: 7540-7548.
60. Van Kampen KR, Shi Z, Gao P, Zhang J, Foster KW, et al. (2005) Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23: 1029-1036.